Stock Exchange: NYSE
Symbol: ABBV
Sector: Healthcare
Industry: Drug Manufacturers - General
About AbbVie Inc
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc Stats
| Previous close: | Daily change: |
| 171.73 | 3.04% |
| 52-Week High: | 52-Week Low: |
| 207.32 | 137.65 |
| Market Cap: | Beta: |
| 312.7 Billion | 0.61 |
AbbVie Inc Key Financials
| P/E Ratio: | Revenues: | Revenue Growth: | Gross Margin: |
| 61.6551 | 55.5 Billion | 3.80% | 70.34% |
| Dividend Yield: | Net Income: | Earnings Growth: | Net Income Margin: |
| 3.82% | 5.1 Billion | -12.30% | 9.22% |
| P/E Ratio: | Revenues: |
| 61.6551 | 55.5 Billion |
| Dividend Yield: | Net Income: |
| 3.82% | 5.1 Billion |
| Revenue Growth: | Gross Margin: |
| 3.80% | 70.34% |
| Earnings Growth: | Net Income Margin: |
| -12.30% | 9.22% |
| Parameters | Stocks Investing |
|---|---|
| Stock Currency | USD |
| Dividend Paying | Yes |
| Fractional Shares | Yes |
| Maximum Shares | 100 Shares |
| Tick value per 1 share | 0.01 USD |
| Trading Commission | 0% |
| Minimum Price Increment | 0.01 |
| Limit and Stop Levels | 0.0 |
| Negative balance protection | No |
| Swap free days allowance | N/A |
| Own the underlying Asset | No |
| Platform symbol | ABBV.USX |